[
  {
    "ts": "2025-08-04T21:35:02+00:00",
    "headline": "Encompass Health (EHC) Q2 Earnings and Revenues Surpass Estimates",
    "summary": "Encompass Health (EHC) delivered earnings and revenue surprises of +16.67% and +2.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finance.yahoo.com/news/encompass-health-ehc-q2-earnings-213502434.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ca0b7e38-d622-3a2c-9942-331c0027271d",
      "content": {
        "id": "ca0b7e38-d622-3a2c-9942-331c0027271d",
        "contentType": "STORY",
        "title": "Encompass Health (EHC) Q2 Earnings and Revenues Surpass Estimates",
        "description": "",
        "summary": "Encompass Health (EHC) delivered earnings and revenue surprises of +16.67% and +2.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
        "pubDate": "2025-08-04T21:35:02Z",
        "displayTime": "2025-08-04T21:35:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba",
          "originalWidth": 900,
          "originalHeight": 745,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J2T_cDhaoaaQj0soPS_nNw--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba.cf.webp",
              "width": 900,
              "height": 745,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sWMlcbg78JI.iCrZWAER9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/encompass-health-ehc-q2-earnings-213502434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/encompass-health-ehc-q2-earnings-213502434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DVA"
            },
            {
              "symbol": "EHC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T12:00:00+00:00",
    "headline": "Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization",
    "summary": "VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a weekCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL tria",
    "url": "https://finance.yahoo.com/news/akebia-initiates-vafseo-vadadustat-post-120000756.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "27990dd9-9128-3568-a089-1250be6e2ea7",
      "content": {
        "id": "27990dd9-9128-3568-a089-1250be6e2ea7",
        "contentType": "STORY",
        "title": "Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization",
        "description": "",
        "summary": "VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a weekCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL tria",
        "pubDate": "2025-08-04T12:00:00Z",
        "displayTime": "2025-08-04T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/849c7df46f1ea545ac15df5f8a47e6b1",
          "originalWidth": 4321,
          "originalHeight": 1761,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RlzKdoLm0SQudsf4h9YvVg--~B/aD0xNzYxO3c9NDMyMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/849c7df46f1ea545ac15df5f8a47e6b1.cf.webp",
              "width": 4321,
              "height": 1761,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a5_CzxY8Vcp3JCQO3Btxnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/849c7df46f1ea545ac15df5f8a47e6b1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/akebia-initiates-vafseo-vadadustat-post-120000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/akebia-initiates-vafseo-vadadustat-post-120000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DVA"
            },
            {
              "symbol": "AKBA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T03:05:02+00:00",
    "headline": "DaVita (DVA) To Report Earnings Tomorrow: Here Is What To Expect",
    "summary": "Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting results this Tuesday after market hours. Here’s what to look for.",
    "url": "https://finance.yahoo.com/news/davita-dva-report-earnings-tomorrow-030502724.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "854f8832-a018-3386-bbeb-f0297614fd84",
      "content": {
        "id": "854f8832-a018-3386-bbeb-f0297614fd84",
        "contentType": "STORY",
        "title": "DaVita (DVA) To Report Earnings Tomorrow: Here Is What To Expect",
        "description": "",
        "summary": "Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting results this Tuesday after market hours. Here’s what to look for.",
        "pubDate": "2025-08-04T03:05:02Z",
        "displayTime": "2025-08-04T03:05:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1c7567012554a1dbc086729cde9f4795",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "DVA Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4TnYLyTdXGGvoFRhuJkfKA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1c7567012554a1dbc086729cde9f4795.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nuxyJbIzKFcPZE47ankl8g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1c7567012554a1dbc086729cde9f4795.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/davita-dva-report-earnings-tomorrow-030502724.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/davita-dva-report-earnings-tomorrow-030502724.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DVA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]